PDF(Pubmed)
Abstract：
BACKGROUND: Concentrations of metoprolol in exhaled breath condensate (EBC) have not been investigated. Herein, we aim to determine the metoprolol levels in EBC, plasma, and urine samples.
METHODS: Biological samples were collected from 39 patients receiving metoprolol. Metoprolol was determined using liquid chromatography mass spectrometery. The obtained metoprolol levels in biological fluids were investigated for possible inter-correlations.
RESULTS: Acceptable linearity was obtained with coefficient of determinations equal to 0.9998, 0.9941, and 0.9963 for EBC, plasma, and urine samples, respectively. The calibration curves were linear in the ranges of 0.6-500, 0.4-500, and 0.7-10,000 µg·L- 1 regarding EBC, plasma, and urine samples, respectively. The detection and quantification limits were (0.18, 0.12, and 0.21 µg·L- 1) and (0.60, 0.40, and 0.70 µg·L- 1) for EBC, plasma, and urine samples, respectively. The relative standard deviations for the intra- and inter-day replications were obtained between 5.2 and 6.1 and 3.3-4.6%, respectively. The obtained mean metoprolol levels in EBC, plasma, and urine samples of 39 patients were 5.35, 70.76, and 1943.1 µg·L- 1. There were correlations between daily dose and plasma and urinary concentrations of metoprolol in the investigated samples, whereas no significant correlation was observed for daily dose and EBC levels. The correlation among plasma-urine levels was significant, however, the non-significant correlation was obtained between plasma and EBC concentrations.
CONCLUSIONS: Metoprolol levels varied widely due to the metabolic pattern of the Azeri population, different dosages received by the patients, formulation effects, age, sex, and interactions with the co-administered drugs. A poor correlation of EBC-plasma concentrations and a significant correlation of plasma-urine concentrations were observed. Further investigations are required to provide the updated services to personalized medicine departments.
METHODS: Biological samples were collected from 39 patients receiving metoprolol. Metoprolol was determined using liquid chromatography mass spectrometery. The obtained metoprolol levels in biological fluids were investigated for possible inter-correlations.
RESULTS: Acceptable linearity was obtained with coefficient of determinations equal to 0.9998, 0.9941, and 0.9963 for EBC, plasma, and urine samples, respectively. The calibration curves were linear in the ranges of 0.6-500, 0.4-500, and 0.7-10,000 µg·L- 1 regarding EBC, plasma, and urine samples, respectively. The detection and quantification limits were (0.18, 0.12, and 0.21 µg·L- 1) and (0.60, 0.40, and 0.70 µg·L- 1) for EBC, plasma, and urine samples, respectively. The relative standard deviations for the intra- and inter-day replications were obtained between 5.2 and 6.1 and 3.3-4.6%, respectively. The obtained mean metoprolol levels in EBC, plasma, and urine samples of 39 patients were 5.35, 70.76, and 1943.1 µg·L- 1. There were correlations between daily dose and plasma and urinary concentrations of metoprolol in the investigated samples, whereas no significant correlation was observed for daily dose and EBC levels. The correlation among plasma-urine levels was significant, however, the non-significant correlation was obtained between plasma and EBC concentrations.
CONCLUSIONS: Metoprolol levels varied widely due to the metabolic pattern of the Azeri population, different dosages received by the patients, formulation effects, age, sex, and interactions with the co-administered drugs. A poor correlation of EBC-plasma concentrations and a significant correlation of plasma-urine concentrations were observed. Further investigations are required to provide the updated services to personalized medicine departments.
摘要：
背景：尚未研究呼出气冷凝液（EBC）中美托洛尔的浓度。在这里，我们的目标是确定EBC中的美托洛尔水平，等离子体,还有尿液样本.
方法：从39名接受美托洛尔的患者中收集生物样本。使用液相色谱质谱测定美托洛尔。研究了生物流体中获得的美托洛尔水平的可能相互关系。
结果：EBC的决定系数等于0.9998、0.9941和0.9963，获得了可接受的线性，等离子体,还有尿液样本,分别。关于EBC，校准曲线在0.6-500、0.4-500和0.7-10,000µg·L-1的范围内呈线性关系，等离子体,还有尿液样本,分别。EBC的检测和定量限分别为（0.18、0.12和0.21µg·L-1）和（0.60、0.40和0.70µg·L-1），等离子体,还有尿液样本,分别。日内和日间重复的相对标准偏差在5.2和6.1和3.3-4.6％之间获得，分别。EBC中获得的美托洛尔平均水平，等离子体,39例患者的尿液样本分别为5.35、70.76和1943.1µg·L-1。研究样品中美托洛尔的日剂量与血浆和尿浓度之间存在相关性，而每日剂量和EBC水平没有观察到显著的相关性。血浆-尿液水平之间的相关性是显著的，然而,血浆和EBC浓度之间无显著相关性.
结论：美托洛尔水平因阿塞拜疆人群的代谢模式而变化很大，患者接受的不同剂量，配方效应，年龄,性别,以及与共同给药的药物的相互作用。观察到EBC-血浆浓度的相关性较差，血浆-尿液浓度的相关性显着。需要进一步调查才能为个性化医疗部门提供最新服务。
方法：从39名接受美托洛尔的患者中收集生物样本。使用液相色谱质谱测定美托洛尔。研究了生物流体中获得的美托洛尔水平的可能相互关系。
结果：EBC的决定系数等于0.9998、0.9941和0.9963，获得了可接受的线性，等离子体,还有尿液样本,分别。关于EBC，校准曲线在0.6-500、0.4-500和0.7-10,000µg·L-1的范围内呈线性关系，等离子体,还有尿液样本,分别。EBC的检测和定量限分别为（0.18、0.12和0.21µg·L-1）和（0.60、0.40和0.70µg·L-1），等离子体,还有尿液样本,分别。日内和日间重复的相对标准偏差在5.2和6.1和3.3-4.6％之间获得，分别。EBC中获得的美托洛尔平均水平，等离子体,39例患者的尿液样本分别为5.35、70.76和1943.1µg·L-1。研究样品中美托洛尔的日剂量与血浆和尿浓度之间存在相关性，而每日剂量和EBC水平没有观察到显著的相关性。血浆-尿液水平之间的相关性是显著的，然而,血浆和EBC浓度之间无显著相关性.
结论：美托洛尔水平因阿塞拜疆人群的代谢模式而变化很大，患者接受的不同剂量，配方效应，年龄,性别,以及与共同给药的药物的相互作用。观察到EBC-血浆浓度的相关性较差，血浆-尿液浓度的相关性显着。需要进一步调查才能为个性化医疗部门提供最新服务。
